These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 25414155)

  • 21. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
    Eur J Endocrinol; 2017 Jan; 176(1):77-86. PubMed ID: 27777261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
    von Scholten BJ; Persson F; Rosenlund S; Eugen-Olsen J; Pielak T; Faber J; Hansen TW; Rossing P
    Diabetes Obes Metab; 2017 Jun; 19(6):901-905. PubMed ID: 28105731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
    Jorsal A; Kistorp C; Holmager P; Tougaard RS; Nielsen R; Hänselmann A; Nilsson B; Møller JE; Hjort J; Rasmussen J; Boesgaard TW; Schou M; Videbaek L; Gustafsson I; Flyvbjerg A; Wiggers H; Tarnow L
    Eur J Heart Fail; 2017 Jan; 19(1):69-77. PubMed ID: 27790809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.
    O'Connell JE; Jardine AG; Davidson G; Connell JM
    J Hypertens; 1992 Mar; 10(3):271-7. PubMed ID: 1315825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic angiotensin-converting enzyme inhibition may improve sodium excretion in cardiac transplant hypertension.
    Schwietzer GK; Hartmann A; Kober G; Jungmann E; Stratmann D; Kaltenbach M; Schoeppe W
    Transplantation; 1995 Apr; 59(7):999-1004. PubMed ID: 7709462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
    Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of atrial natriuretic peptide (8-33-Met ANP) in patients with hypertension.
    Franco-Saenz R; Somani P; Mulrow PJ
    Am J Hypertens; 1992 May; 5(5 Pt 1):266-75. PubMed ID: 1533767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.
    Imamura S; Hirai K; Hirai A
    Tohoku J Exp Med; 2013 Sep; 231(1):57-61. PubMed ID: 24064677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Margulies KB; Hernandez AF; Redfield MM; Givertz MM; Oliveira GH; Cole R; Mann DL; Whellan DJ; Kiernan MS; Felker GM; McNulty SE; Anstrom KJ; Shah MR; Braunwald E; Cappola TP;
    JAMA; 2016 Aug; 316(5):500-8. PubMed ID: 27483064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.
    Gutzwiller JP; Tschopp S; Bock A; Zehnder CE; Huber AR; Kreyenbuehl M; Gutmann H; Drewe J; Henzen C; Goeke B; Beglinger C
    J Clin Endocrinol Metab; 2004 Jun; 89(6):3055-61. PubMed ID: 15181098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic imidazoline receptor activation in spontaneously hypertensive rats.
    Menaouar A; El-Ayoubi R; Jankowski M; Gutkowska J; Mukaddam-Daher S
    Am J Hypertens; 2002 Sep; 15(9):803-8. PubMed ID: 12219876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged decrease in blood pressure after atrial natriuretic peptide infusion in essential hypertension: a new anti-pressor mechanism?
    Singer DR; Markandu ND; Buckley MG; Miller MA; Sugden AL; Sagnella GA; MacGregor GA
    Clin Sci (Lond); 1989 Sep; 77(3):253-8. PubMed ID: 2530019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice.
    Baggio LL; Ussher JR; McLean BA; Cao X; Kabir MG; Mulvihill EE; Mighiu AS; Zhang H; Ludwig A; Seeley RJ; Heximer SP; Drucker DJ
    Mol Metab; 2017 Nov; 6(11):1339-1349. PubMed ID: 29107282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind placebo-controlled trial of the effects of short-term potassium supplementation on blood pressure and atrial natriuretic peptide in normotensive women.
    Barden A; Beilin LJ; Vandongen R; Puddey IB
    Am J Hypertens; 1991 Mar; 4(3 Pt 1):206-13. PubMed ID: 1828348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
    JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
    Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men.
    Hunt PJ; Espiner EA; Richards AM; Yandle TG; Frampton C; Nicholls MG
    Am J Physiol; 1995 Dec; 269(6 Pt 2):R1397-403. PubMed ID: 8594942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.